Alex Rosen
Director/Board Member at Upstream Bio, Inc.
Alex Rosen active positions
| Companies | Position | Start | End |
|---|---|---|---|
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Director/Board Member | 08/06/2023 | - |
Career history of Alex Rosen
Former positions of Alex Rosen
| Companies | Position | Start | End |
|---|---|---|---|
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Private Equity Investor | 01/07/2016 | - |
Training of Alex Rosen
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| Private Equity Investor | 1 |
| Masters Business Admin | 1 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Finance | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
- Stock Market
- Insiders
- Alex Rosen
- Experience
